Feed aggregator

PALO ALTO, Calif.--(BUSINESS WIRE)--The Skoll Foundation is pleased to announce the five organizations that will receive the 2025 Skoll Award for Social Innovation. The prestigious $2 million award shines a light on the extraordinary leaders and organizations advancing transformational social change to create a more sustainable, peaceful, and prosperous world for all. The 2025 class of social innovators includes social entrepreneurs, movement builders, system orchestrators, and global coalition

--(BUSINESS WIRE)--UnitedHealth Group Announces Earnings Release Date

COSTA MESA, Calif.--(BUSINESS WIRE)--Experian announces an additional $100,000 in consumer debt relief for Louisiana families, adding to its $5 million initiative announced in March.

LONDON & LOS ANGELES--(BUSINESS WIRE)--Crescent Capital Group LP, a leading alternative credit investment firm, announced today that its European Specialty Lending strategy provided unitranche financing to support VIA equity’s strategic partnership with Saarni Cloud, a Finland-based Software as a Service (SaaS) provider for human capital management. VIA equity, a leading Northern European private equity firm, acquired a minority stake to become the lead investor, with Saarni’s existing investor

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of AZEK Company Inc. (NYSE: AZEK) to James Hardie Industries plc is fair to AZEK shareholders. Under the terms of the proposed transaction, AZEK shareholders will receive $26.45 in cash and 1.0340 ordinary shares of James Hardie for each share of AZEK common stock they own. Upon completion of the proposed transaction, AZEK shareholders are expected to own approximately 26% of the combined

LOS ANGELES--(BUSINESS WIRE)--SANA Investors Have Opportunity to Lead Sana Biotechnology, Inc. Securities Fraud Lawsuit with the Schall Law Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of purchasers of securities of Novo Nordisk A/S (NYSE: NVO) between November 2, 2022 and December 19, 2024. Novo describes itself as a “healthcare company, focused on the research, development, manufacturing, and distribution of pharmaceutical productions globally.” For more information, submit a form, email attorney Phillip Kim, or give us a call at